Page 50 - Test PDF v5

« Back to Contents VULVAR CANCER

LiFE re

Literature for ENYGO

Treatment of vaginal cancer

Editor Elis Ismail Robertson et al., based on the prospective data registry, reported a
change in prognostic impression in 51 % and demonstrated a change
Descriptive summary in patient management (defined as a change to/from observation or
additional imaging to/from biopsy or treatment) following FDG-PET/
PDQ (Physician Data Query) is a comprehensive, peer-reviewed, evi- CT after 36 % of studies in patients with vulvar and vaginal carci-
dence-based, National Cancer Institute source of cancer information noma [4]. FDG-PET/CT identified nodal disease in 35 % of patients
for health professionals. Recently, a summary on the treatment of imaged. The authors concluded that FDG-PET/CT may play an impor-
vaginal cancer was released with updated statistics. The American tant role in the staging of both vulvar and vaginal cancer.
Cancer Society estimates 5,950 new cases and 1,110 deaths from
vulvar cancer in the United States in 2016 [1]. Ozgul et al. presented a surgical video with en bloc radical removal of
uterus and vagina in a patient with clinical early-stage vaginal cancer.
Greenwalt et al. retrospectively reviewed medical records of 71
patients with primary vaginal adenocarcinoma or squamous cell Akino et al. presented a case of vaginal cancer that occurred after
carcinoma treated with definitive radiotherapy [2]. The majority of usage of a vaginal pessary in a patient with an immunocompromised
patients (93 %) were treated with external beam radiation therapy condition.
(EBRT) plus brachytherapy. The distant metastasis-free survival rate
was 87 % at 5 years and 85 % at 10 years. Recurrence generally
occurred within 5 years of treatment but usually occurred within
2 years. The study also supports electively irradiating the inguinal
nodes in patients with tumours in the distal one third of the vagina.

Chang et al., in their multi-institutional retrospective study, also
focused on radiotherapy in 138 patients with primary vaginal cancer
[3]. They presented results showing that the 5-year overall survival,
cancer-specific survival (CSS), and progression-free survival (PFS)
rates were 68 %, 80 %, and 68.7 %, respectively. A lower FIGO
stage and prior hysterectomy were favourable prognostic factors
of cancer-specific survival. The HPV status was not related to the
survival outcome.

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract
1 Vaginal Cancer Treatment (PDQ®): Health Professional Version. 2016 Feb 9.
PDQ Adult Treatment PDQ Cancer Information http://www.ncbi.nlm.nih.gov/books/
2 Outcomes of definitive radiation therapy for primary vaginal carcinoma. Editorial Board Summaries [Internet] NBK65801/

Greenwalt JC et al. Am J Clin Oncol. https://www.ncbi.nlm.nih.gov/
pubmed/24136141
3 Definitive treatment of primary vaginal cancer with radiotherapy: multi-insti- Chang JH et al. J Gynecol Oncol.
tutional retrospective study of the Korean Radiation Oncology Group (KROG https://www.ncbi.nlm.nih.gov/
12-09). Gynecol Oncol. pubmed/26768782
Int J Gynecol Cancer.
4 The impact of FDG - PET/CT in the management of patients with vulvar and Robertson NL et al. https://www.ncbi.nlm.nih.gov/
vaginal cancer. pubmed/26790773

5 Radical hysterecomy and abdominal vaginectomy for primary vaginal cancer. Ozgul N et al. https://www.ncbi.nlm.nih.gov/
pubmed/26825828
6 Vaginal cancer possibly caused by pessary and immunocompromised conditi- Akino N et al. J Obstet Gynaecol Res.
on: multiple risk factors may influence vaginal cancer development. https://www.ncbi.nlm.nih.gov/
pubmed/26914159

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 50